2026-03-06 01:32Financial Data and Key Metrics Changes - Total oncology revenue for 2025 was $286 million, including $71 million from R&D-related upfront and milestone revenues [5] - Net income recorded was $457 million, primarily due to a one-time gain from the SHPL divestment of $160 million; core operations remained profitable excluding this gain [5] - R&D expenses for 2025 were $148 million, lower than in 2024 due to many late-stage trials nearing completion [6] - Cash position strengthened to approximately $1.4 billion, allowing for accelerated global development and exploration of in-licensing and M&A opportunities [4][7] Business Line Data and Key Metrics Changes - Ex-China FRUZAQLA sales grew by 26% year-over-year, totaling $366 million in in-market sales [3] - China sales rebounded in the second half of 2025, achieving 21% growth compared to the first half [3] - ORPATHYS and SULANDA accounted for 11% of total 2025 in-market sales, facing challenges due to competition [10] Market Data and Key Metrics Changes - In the U.S., sales faced headwinds from Medicare Part D redesign, impacting overall performance [9] - China sales under the brand name ELUNATE experienced a -13% decline in the first half but rebounded with 33% growth in the second half [9] - The ITP market potential in China is significant, with over 250,000 actively treated patients, representing an addressable market of $500 million to $700 million [19] Company Strategy and Development Direction - The company aims to accelerate global development of ATTC programs while exploring business development opportunities [25] - Focus on expanding the hematology portfolio with new products and establishing a dedicated sales and marketing team for this specialized area [11][71] - The strategy includes potential partnerships for the ATTC platform to validate and enhance its value [50] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, with oncology revenue guidance set between $330 million and $450 million, reflecting strong growth expectations [7][25] - The company anticipates continued growth from new indications and the global expansion of FRUZAQLA [31] - Management highlighted the importance of maintaining a balance between existing commercial products and emerging opportunities from the ATTC platform [52] Other Important Information - The company has advanced two ATTC programs into clinical trials, with significant market potential anticipated [4] - The SAFFRON and SANOVO readouts are expected in mid-2026, which are critical for future growth [31][24] Q&A Session Summary Question: Can you elaborate on the oncology guidance for 2026? - Management indicated that the guidance reflects strong growth expectations, particularly from new indications and continued recovery in sales [30][31] Question: What is the status of the SAFFRON readout? - The SAFFRON readout is expected to occur in mid-2026 [31][36] Question: Can you provide details on the ATTC platform candidates? - A251 is currently enrolling HER2 expressing solid tumor patients, focusing on post-HER2 treatment settings [31] Question: How are commercial dynamics expected to stabilize in 2026? - Management noted that turnover rates have decreased and the sales team has been restructured to focus on top-tier hospitals, which should improve performance [41][42] Question: What is the impact of MET testing adoption on savolitinib? - No additional information was provided on the influence of MET testing adoption on savolitinib uptake [48] Question: What is the partnering strategy for the ATTC platform? - The company is considering licensing out some programs while maintaining control over others to maximize long-term value [50] Question: What is the guidance for R&D expenses this year? - Management indicated a desire to ramp up R&D investment to a range of $250 million to $300 million [60] Question: Can you elaborate on the in-licensing and M&A strategy? - The company is open to in-licensing late-stage commercial assets or complementary assets, given its strong cash position [63] Question: How will the move into hematology products affect sales and marketing investments? - A new business unit with dedicated sales and marketing capabilities has been established to address the hematology market [71]